Nystagmus Eye Diseases Nystagmus and other irregular eye movements
Conditions
Interventions
Gabapentin will be given at a starting dose of 1 capsule (300 mg) per day for 3 days
then 1 capsule twice per day for 3 days
then 1 capsule three times per day for 3 days, and finally 1 capsule four times per day (total = 1200 mg/day) for the final remaining 5 days. The final evaluation of vision and eye movements will be m
then 1 capsule three times per day for 3 days, and finally 1 capsule four times per day (total = 40 mg/day) for the final remaining 5 days. The final evaluation of vision and eye movements will be mad
Sponsors
National Eye Institute/National Institutes of Health (USA)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with acquired nystagmus due to multiple sclerosis, stroke (brain stem) or cerebellar disease (such as Chiari malformation) 2. Medically stable 3. Able to give informed consent 4. Can understand and cooperate with the testing 5. Aged 18 years or older, both sexes
Exclusion criteria
Exclusion criteria: 1. Not able to understand or follow the instructions of each protocol 2. Too frail to sit in the vestibular chair during testing for the required period 3. Judged to be at risk for falls (many patients with poor balance adjust to this, and are not at risk of falls) 4. History of mental illness or confusion 5. Known to have an allergy to gabapentin or memantine 6. Pregnant, since the safety of memantine in pregnancy is unknown
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Visual acuity of each eye, measured at far or near prior to, and on the final day of, treatment with each drug 2. Median eye speed, measured with the magnetic search coil technique, prior to, and on the final day of, treatment with each drug Measured at the end of 14 days on each medicine. | — |
Secondary
| Measure | Time frame |
|---|---|
| The patient's overall assessment of whether either drug improves their vision and is generally well tolerated, measured at the end of 14 days on each medicine. | — |
Countries
United States of America
Outcome results
None listed